GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » EV-to-FCF

UBX (Unity Biotechnology) EV-to-FCF : -0.47 (As of Dec. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Unity Biotechnology's Enterprise Value is $10.53 Mil. Unity Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.54 Mil. Therefore, Unity Biotechnology's EV-to-FCF for today is -0.47.

The historical rank and industry rank for Unity Biotechnology's EV-to-FCF or its related term are showing as below:

UBX' s EV-to-FCF Range Over the Past 10 Years
Min: -9.04   Med: -0.34   Max: 2.04
Current: -0.47

During the past 8 years, the highest EV-to-FCF of Unity Biotechnology was 2.04. The lowest was -9.04. And the median was -0.34.

UBX's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs UBX: -0.47

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-15), Unity Biotechnology's stock price is $1.12. Unity Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.270. Therefore, Unity Biotechnology's PE Ratio (TTM) for today is At Loss.


Unity Biotechnology EV-to-FCF Historical Data

The historical data trend for Unity Biotechnology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology EV-to-FCF Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -2.88 -3.10 -1.32 0.10 -0.44

Unity Biotechnology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.44 -0.45 -0.43 -0.73

Competitive Comparison of Unity Biotechnology's EV-to-FCF

For the Biotechnology subindustry, Unity Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unity Biotechnology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's EV-to-FCF falls into.



Unity Biotechnology EV-to-FCF Calculation

Unity Biotechnology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10.533/-22.535
=-0.47

Unity Biotechnology's current Enterprise Value is $10.53 Mil.
Unity Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unity Biotechnology  (NAS:UBX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Unity Biotechnology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.12/-1.270
=At Loss

Unity Biotechnology's share price for today is $1.12.
Unity Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Unity Biotechnology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Executives
Alexander Hieu Nguyen officer: See Remarks C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Anirvan Ghosh director, officer: Chief Executive Officer C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Lynne Marie Sullivan officer: See Remarks C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar director C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Nathaniel E David director, officer: President C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy officer: See Remarks 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kristina Burow director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Camille D Samuels director 2463 JACKSON ST., SAN FRANCISCO CA 94115
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Dan Marquess officer: Chief Scientific Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005